Kedrion Biopharma

🌱 𝐎𝐮𝐫 𝟐𝟎𝟐𝟑 𝐒𝐮𝐬𝐭𝐚𝐢𝐧𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐑𝐞𝐩𝐨𝐫𝐭 𝐢𝐬 𝐨𝐮𝐭 🌍    We are thrilled to announce the release of our latest 𝐒𝐮𝐬𝐭𝐚𝐢𝐧𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐑𝐞𝐩𝐨𝐫𝐭 𝐟𝐨𝐫 𝟐𝟎𝟐𝟑! This report highlights the strides we've made towards sustainability across all facets of our operations.    Sustainability is not just a goal-it's at the core of our Values. It involves the ability to anticipate tomorrow's events with the confidence achieved through impactful actions initiated today. This past year, our sustainability efforts have grown hand in hand with the economic and financial advancements of the new Kedrion.   Key highlights from this Report include: 🤝 Community engagement and partnerships 🌿 Environmental initiatives and progress 📈 Impact metrics and future goals Moving forward, we remain committed to investing in initiative that enhance our operations, ensuring 𝐭𝐡𝐞 𝐡𝐢𝐠𝐡𝐞𝐬𝐭 𝐬𝐭𝐚𝐧𝐝𝐚𝐫𝐝𝐬 𝐨𝐟 𝐬𝐨𝐜𝐢𝐚𝐥 𝐚𝐧𝐝 𝐞𝐧𝐯𝐢𝐫𝐨𝐧𝐦𝐞𝐧𝐭𝐚𝐥 𝐩𝐞𝐫𝐟𝐨𝐫𝐦𝐚𝐧𝐜𝐞, 𝐭𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲, 𝐚𝐧𝐝 𝐚𝐜𝐜𝐨𝐮𝐧𝐭𝐚𝐛𝐢𝐥𝐢𝐭𝐲. #Sustainability #2023SustainabilityReport #GreenFuture #CorporateResponsibility ➡️ https://lnkd.in/dP-BZVxg

The official adoption of the #SoHORegulation by the Council of the European Union represents a crucial step towards the growth of plasma collection. Kedrion will work side by side PPTA to ensure donor health and guarantee a resilient supply of life-saving plasma-derived medicines to patients across Europe.

🌍 𝐖𝐫𝐚𝐩 𝐮𝐩 𝐨𝐟 𝐭𝐡𝐞 𝟐𝟎𝟐𝟒 𝐖𝐨𝐫𝐥𝐝 𝐅𝐞𝐝𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐇𝐞𝐦𝐨𝐩𝐡𝐢𝐥𝐢𝐚 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬 🌟  🎥 Watch the video to catch the most impactful moments from this year's conference. From groundbreaking research to inspiring patient stories, this congress showcased the latest advancements in bleeding disorders care and management. Let's continue to collaborate and drive progress in the hemophilia and other coagulations disorder community! #WFHCongress2024 #TreatmentForAll #GlobalHealth #BleedingDisorder World Federation of Hemophilia / Fédération mondiale de l'hémophilie

🌍 𝐄𝐧𝐬𝐮𝐫𝐢𝐧𝐠 𝐄𝐪𝐮𝐢𝐭𝐚𝐛𝐥𝐞 𝐀𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐁𝐥𝐞𝐞𝐝𝐢𝐧𝐠 𝐃𝐢𝐬𝐨𝐫𝐝𝐞𝐫𝐬 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬: 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 𝐌𝐫. 𝐆𝐚𝐫𝐫𝐢𝐝𝐨, 𝐏𝐫𝐞𝐬𝐢𝐝𝐞𝐧𝐭 𝐨𝐟 𝐖𝐅𝐇 During the 𝟐𝟎𝟐𝟒 𝐖𝐨𝐫𝐥𝐝 𝐅𝐞𝐝𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐇𝐞𝐦𝐨𝐩𝐡𝐢𝐥𝐢𝐚 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬, we had the privilege of speaking to Mr. Garrido (President of World Federation of Hemophilia / Fédération mondiale de l'hémophilie), about a critical topic affecting patients globally: 𝐞𝐪𝐮𝐢𝐭𝐚𝐛𝐥𝐞 𝐚𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬. In our interview, he shared compelling perspectives on why this issue matters and what steps can be taken to bridge gaps in care. Bleeding disorders are a condition that require lifelong management, and access to therapies can significantly impact patients' lives. As advocates for health equity, it's crucial to address disparities in access, ensuring that everyone, regardless of location or resources, can receive the treatments they need. More than 3000 attendees gathered at this year’ World Federation of Hemophilia Congress, recently held in Madrid, as it is recognized as one of the most important appointments for the bleeding disorders communities. ⤵️ 𝐖𝐚𝐭𝐜𝐡 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐢𝐧𝐭𝐞𝐫𝐯𝐢𝐞𝐰 𝐡𝐞𝐫𝐞 to gain valuable insights. #WFHCongress2024 #TreatmentForAll #GlobalHealth #BleedingDisorder

🌟 𝟏𝟎𝟎 𝐘𝐞𝐚𝐫𝐬 𝐨𝐟 𝐬𝐞𝐫𝐯𝐢𝐧𝐠 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬: 𝐊𝐞𝐝𝐫𝐢𝐨𝐧 𝐡𝐨𝐧𝐨𝐫𝐬 𝐭𝐡𝐞 𝐋𝐞𝐠𝐚𝐜𝐲 𝐢𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐨𝐟 𝐨𝐮𝐫 𝐆𝐨̈𝐝𝐨̈𝐥𝐥𝐨̋ 𝐬𝐢𝐭𝐞. 🌟 This year, our production site located in Gödöllő, near Budapest, Hungary, proudly celebrates its 100th anniversary. For a century, this facility has been a cornerstone of healthcare advancement in the country, driven by continuous innovation and a commitment to pushing the boundaries of research for the benefit of patients. Kedrion acquired this facility in 2008, making it a key player in its global industrial network, building strong relationships with the local communities and distinguishing itself for its commitment to the region. Yesterday, celebrations of this incredible milestone kicked off at the site with a crowded grand opening hosted by Laszlo Siadik, Managing Director of our Hungarian subsidiary, a message from our CEO Ugo Di Francesco and the presence - among others - of Gödöllő's Mayor, György Gémesi. This 100-year history wouldn't have been possible without the dedication of all who came before us. A special thanks to our employees who work every day to transform plasma into life-saving therapies.

Bob Rossilli, CCO of Kedrion Biopharma - USA, explains the benefits of membership with the Plasma Protein Therapeutics Association. Ready to become a member? Click here to get started: https://lnkd.in/emRt8ddF

Motherhood. It's a whirlwind of sticky kisses, sleepless nights, and a love that defies definition. But let's be honest, it's also hard. For working moms, the daily juggle is real. From managing conference calls with spit-up stains on blouses, negotiating deadlines with one hand rocking a fussy baby, and somehow finding the strength to be everything to everyone - at home and at work. At Kedrion Biopharma, we see you. We see the strength it takes to navigate the complexities of motherhood, especially when facing the additional challenge of a rare disease. To all the mothers fighting for their children's health, we stand with you. You are warriors, nurturers, and miracle makers. This Mother's Day, and every day, we celebrate the extraordinary strength of mothers. Let's lift each other up, share our stories, and keep pushing for a brighter future for all. If you want to learn more about how we stay connected to our communities and support mothers facing daily battles with their children's rare diseases, visit the "Our Stories" section on kedrion.com. *Yes, this is a reality check – in the photo you see one of our leaders handling a call while being a mother

It is particularly important 𝐢𝐧 𝐫𝐚𝐫𝐞 𝐚𝐧𝐝 𝐮𝐥𝐭𝐫𝐚-𝐫𝐚𝐫𝐞 𝐝𝐢𝐬𝐞𝐚𝐬𝐞, that all those involved, from scientific bodies to patient associations, from industry players to key opinion leaders, work together with a double goal - raising general awareness of the disease, its consequences, and educating physicians and healthcare providers to recognize the symptoms and reach a diagnosis sooner. To mark the 𝐟𝐢𝐫𝐬𝐭 𝐂𝐨𝐧𝐠𝐞𝐧𝐢𝐭𝐚𝐥 𝐏𝐥𝐚𝐬𝐦𝐢𝐧𝐨𝐠𝐞𝐧 𝐃𝐞𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐲 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐃𝐚𝐲, promoted globally on May 4th, we would like to recognize everyone at our Laval, Canada, manufacturing site for their long-standing committment to 𝐦𝐚𝐤𝐢𝐧𝐠 𝐚 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐢𝐧 𝐭𝐡𝐞 𝐥𝐢𝐯𝐞𝐬 𝐨𝐟 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 struggling with Congenital Plasminogen Deficiency.

✨ We are thrilled to announce our new 𝐆𝐥𝐨𝐛𝐚𝐥 𝐂𝐨𝐝𝐞 𝐨𝐟 𝐂𝐨𝐧𝐝𝐮𝐜𝐭. ✨ 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲 is one of the foundational Values of our Company. The Kedrion Global Code of Conduct reflects the commitment by our 𝐌𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 and 𝐄𝐦𝐩𝐥𝐨𝐲𝐞𝐞𝐬 to each other and our stakeholders to take the right decisions and to do the right thing as part of our daily job. 𝐒𝐮𝐩𝐩𝐥𝐢𝐞𝐫𝐬 and 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬 working with us are expected to share our same values and commitment. ➡️ Have a look at our 𝐂𝐨𝐝𝐞 and let us have your thoughts! https://lnkd.in/dumMUAzj

✨🚀 On 24 April the European Parliament approved the substances of human origin (SoHO) regulation. As a company that puts the health and well-being of donors and patients first, we are very satisfied with this result, which will have a positive and real impact on #plasma collection and donor safety. The SoHO regulation is an important milestone for #patients across #European Union (EU) who rely on plasma-derived medicines. 🎤 Ferdinando Borgese stated that, "This regulation promises a significant increase in plasma availability, a critical resource for life-saving medicines. By guaranteeing a secure supply within Europe, it can enable a substantial rise in plasmapheresis donations, ultimately benefiting countless patients who rely on these treatments. We remain committed to collaborating with the public and third sectors to ensure donor health."